Oracle plans to officially launch its pharmaceutical applications suite on 13 January.
The move follows the database company?s decision before Christmas to transfer the products out of its consultancy unit, which sold the offerings to customers on an ad hoc project basis, into the higher profile Individual Applications (IA) division.
IA has its own dedicated sales resources, consulting and support staff and currently houses applications aimed at the oil and gas, telecommunications, consumer packaged goods and financial markets.
Other suites likely to be added to the list over the next year include energy, environmental health and safety, government and higher education.
Steve Thomas, Oracle?s senior director of pharmaceuticals, said: ?The pharmaceutical industy is in a state of great and irreversible change with issues such as pricing and the changing regulatory climate leading to fewer companies. The big ones are turning into big development engines that do the expensive bits such as long term trials, which is why we?ve decided to focus on the clinical side.?
The Oracle Pharmaceuticals suite, which began shipping last May, includes the three modules that make up version 3.0 of Oracle Clinical. This enables users to manage the long term clinical trial process and related data management.
Two additional modules, Distributed Studies Conduct, deal with clinical trials across multiple sites, while third party offerings such as Netforce?s Eventnet, also integrated into the suite, ensure that organisations conform to government regulations when involved in adverse event handling.
But Oracle is also evaluating whether to introduce a packaged data warehousing solution specifically for the pharmaceutical market and plans to release a raft of additional modules, developed both inhouse and by third parties over the next couple of years.
Healthcare will also come under the pharmaceutical banner and Oracle is currently deciding whether to build such packages inhouse or license them from partners.
The company currently has approximately 15 pharmaceutical customers worldwide including Genentech, Roche and BASF?s Knoll unit.
Comcast's £29.7bn winning bid more than twice the £13.7bn Rupert Murdoch valued Sky at just eight years ago
A nuclear strike has been considered, but Bruce Willis is nowhere in sight
Spray-on antenna could enable seamless integration of antennas with everyday objects
Parker Solar Probe, TESS and GOLD missions will deliver exciting data, claims NASA